Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock - a systematic review and meta-analysis

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Prkno, Anna ^a   Wacker, Christina ^a   Brunkhorst, Frank M ^a   Schlattmann, Peter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; GLYCOPROTEIN; PROTEIN PRECURSOR;

ANTIMICROBIAL THERAPY; ARTICLE; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; INTENSIVE CARE UNIT; SHOCK, SEPTIC;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; DRUG ADMINISTRATION SCHEDULE; GLYCOPROTEINS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; PROTEIN PRECURSORS; SEPSIS; SHOCK, SEPTIC;

EID: 84889835568     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13157     Document Type: Article

References (39)

1. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007, 33:606-618. 10.1007/s00134-006-0517-7, 17323051.
2. Brunbuisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk-factors, and outcome of severe sepsis and septic shock in adults - a multicenter prospective-study in intensive-care units. JAMA 1995, 274:968-974. 10.1001/jama.1995.03530120060042, 7674528.
3. Heublein S, Hartmann M, Hagel S, Hutagalung R, Brunkhorst FM. Epidemiology of sepsis in German hospitals derived from administrative databases. Infection 2013, 41:S71.
4. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002, 20:1-9.
5. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518. 10.1016/0140-6736(93)90277-N, 8094770.
6. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331. 10.1001/archinternmed.2011.318, 21824946.
7. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of Procalcitonin-Guided Treatment in Patients with Infections: a Systematic Review and Meta-Analysis. Infection 2009, 37:497-507. 10.1007/s15010-009-9034-2, 19826761.
8. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Mueller B. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012, 55:651-662. 10.1093/cid/cis464, 3412690, 22573847.
9. Zhang L, Huang J, Xu T, Lin Y. Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials [article in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2012, 35:275-282.
10. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation. Crit Care Med 2011, 39:1792-1799. 10.1097/CCM.0b013e31821201a5, 21358400.
11. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:2229-2241. 10.1097/CCM.0b013e3181f17bf9, 20729729.
12. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012, 38:940-949. 10.1007/s00134-012-2563-7, 22538461.
13. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011, 53:379-387. 10.1093/cid/cir408, 21810753.
14. Noorani HZ, Adams E, Pitrak D, Belinson S, Aronson N. Future Research Needs on Procalcitonin-Guided Antibiotic Therapy. Future Research Needs Paper No. 29 http://www.effectivehealthcare.ahrq.gov/ehc/products/497/1377/FRN29_Procalcitonin_FinalReport_20130109.pdf.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. 10.7326/0003-4819-151-4-200908180-00135, 19622511.
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
18. Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T. Prevention, diagnosis, treatment, and follow-up care of sepsis - First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI). Anaesthesist 2010, 59:347-370. 10.1007/s00101-010-1719-5, 20414762.
19. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 Higgins JPT, Green S, (updated March 2011) http://www.cochrane-handbook.org.
20. R Development Core Team R: A Language and Environment for Statistical Computing http://www.R-project.org/, R Development Core Team.
21. Schwarzer G. Meta: Meta-Analysis with R, R Package Version: 1.6-1 http://CRAN.R-project.org/package=meta.
22. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005, 58:882-893. 10.1016/j.jclinepi.2005.01.016, 16085191.
23. Collet D. Modelling Survival Data in Medical Research 2003, Boca Raton (FL): CRC Press, 2.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
26. Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, Gonzales H, Feissel M, Cohen Y, Capellier G, Gharbi M, Nardi O. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 2013, 3:e002186. doi:10.1136/bmjopen-2012-00218doi:10.1136/bmjopen-2012-00218, 3586059, 23418298.
27. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417.
28. Hochreiter M, Koehler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83. 10.1186/cc7903, 2717450, 19493352.
29. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328.
30. Nobre V, Harbarth S, Graf L-D, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients - A randomized trial. Am J Respir Crit Care Med 2008, 177:498-505. 10.1164/rccm.200708-1238OC, 18096708.
31. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009, 394:221-226. 10.1007/s00423-008-0432-1, 19034493.
32. Svoboda P, Kantorova I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?. Hepatogastroenterology 2007, 54:359-363.
33. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375. 10.1183/09031936.00053209, 19797133.
34. Bagnenko SF, Shliapnikov SA, Korol'kov AI. Cholangitis and biliary sepsis: problem and ways of solution. Vestn Khir Im I I Grek 2009, 168:17-20.
35. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
36. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals - A challenge to hospital leadership. JAMA 1996, 275:234-240. 10.1001/jama.1996.03530270074035, 8604178.
37. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009, 15:12-15.
38. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42:S82-S89. 10.1086/499406, 16355321.
39. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clin Infect Dis 2009, 49:1175-1184. 10.1086/605630, 19739972.